Policy & Regulation
Gladstone's scientists move research lab focus to SARS-CoV-2
23 March 2020 -

Scientists at Gladstone, an independent state-of-the-art biomedical research institution, are moving the focus of their research labs to the novel virus, SARS-CoV-2 in response to the COVID-19 pandemic, it was reported on Sunday.

The organisation said that its scientists are leveraging their established tools, unique infrastructure, and diverse expertise in virology to develop improved diagnostics, identify targeted treatment strategies, and invent preventative approaches.

Jennifer Doudna, PhD, co-inventor of CRISPR technology, and virologist Melanie Ott, MD, PhD, are collaborating to develop a CRISPR-based method to rapidly measure COVID-19 RNA. Nevan Krogan, PhD, has discovered all of the human host cell proteins that the virus interacts with to hijack the cell's machinery. These proteins serve as novel targets for drug therapies. Leor Weinberger, PhD, has pioneered an innovative approach to fighting the spread of viral pathogens called therapeutic interfering particles, which could be an alternative to a vaccine.

This work is made possible in part because Gladstone has biosafety level 3 (BSL-3) facilities on-site, which are now dedicated to work on COVID-19. The BSL-3 research will be overseen by Melanie Ott, in partnership with UC San Francisco and its Institutional Biosafety Committee and Director of High Containment Laboratories.



Related Headlines